Cardiogenic Shock.

Slides:

Advertisements

Similar presentations

Ole K. Møller-Helgestad 1 In collaboration with CB Poulsen, MD 2 EH Christiansen, MD, PhD 2 JF Lassen, MD, PhD 2 HB Ravn, MD, PhD, DMSc 1 1: Dept. of.

Advertisements

Types of Hemodynamic Support in the Cath Lab.

Detroit Cardiogenic Shock Initiative

IABP-SHOCK II Score Stratifies Patient Risk in CS after AMI

Nat. Rev. Cardiol. doi: /nrcardio

Role of ECMO in Acute Cardiogenic Shock

Mechanical circulatory support

European and US Guidelines

Diabetic Dyslipidemia in Practice

Exploring Early Combination Therapy in PAH

NOACs for Cancer-Associated Thrombosis:

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

NOACs In Long-term VTE Treatment: A State Of The Art Review

Optimizing Therapy for Osteoarthritis

Acute Heart Failure.

The Clinical Enigma of Cardiogenic Shock

When Is Adding Aspirin to NOACs Worth the Risk?

UNDERSTANDING RISK STRATIFICATION IN PAH:

Angiotensin as a Vasopressor in Vasodilatory Shock

Advances in Vasodilatory Shock:

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

American Heart Association Scientific Sessions

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Program Goal. Program Goal Current Stroke Guidelines: AHA/ASA.

Percutaneous Mechanical Circulatory Support Devices

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

When Would You Use Single Inhaler Triple Therapy in COPD?

An Update on PCSK9 Inhibitors

Treating Vasodilatory Shock in the ICU

Evaluating LDL-C Recommendations

HCV Protease Inhibitors in Clinical Practice

New Pathways in Lipid Care

Multidisciplinary Perspectives on Interstitial Lung Diseases

Efficacy and Safety of Edoxaban in Patients With AF and HF

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

How to Optimize TAVR Outcomes

TAVR and the Risk of Thrombosis

Evolving Science of PAH Treatment

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited

Improving Appropriate Access to PCSK9 Inhibitors

Atrial Fibrillation.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

Physiology Myocardial Oxygen Supply and Demanda,b.

Oral Prostanoids and PAH

The Road to Quality Improvement in HER2-Positive Breast Cancer

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

HCV Protease Inhibitors in Clinical Practice

Glucose Management and Statin Therapy

Proteasome Inhibitors and Patients

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Program Goals Background: Anticoagulation in Patients With VTE.

The ABCs of Pharmacogenomics in Clinical Practice

Live on PAH: Breathing Life Into Patients With PAH

Saving the Day.

Managing Pain in the 21st Century

An Update on PCSK9 Inhibitors

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Glucose Management and Statin Therapy

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

Evaluating the Science of Cardiogenic Shock

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Expert Perspectives.

RAASi Enabling in the Modern Era

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Presentation transcript:

Cardiogenic Shock

Program Goals

Cardiogenic Shock

Role of Catheterization in Diagnosing Cardiogenic Shock

Treatment Algorithm for Cardiogenic Shock

pMCS: Meta-Analysis of Impella vs IABP

IABP-SHOCK II Trial

Guideline Recommendations for Circulatory Support in Cardiogenic Shock

CRISP AMI Trial

Hemodynamic Response After IABP Support

IMPRESS Trial

IABP-SHOCK Trial: Outcome Predictors

Device Selection

Types of pMCS Devices

Risk Associated With pMCS Device Insertion

Duration of Therapy

The Shock Team

Device Costs

Abbreviations

Abbreviations (cont)